UNSPSC 51183111: Meglitinide

This classification denotes an anti-diabetic agent with the molecular formula C17H16ClNO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 8V6OK1I088, chemically known as benzoic acid, 4-(2-((5-chloro-2-methoxybenzoyl)amino)ethyl)- but more generally known as meglitinide, which bears US NIH Compound Identifier 41214. European Medicines Agency schedules Meglitinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08713MIG.

UNSPSC 51183111 Meglitinide is a Commodity code covering the procurement of meglitinide medications, a class of rapid-acting insulin secretagogues used to treat type 2 diabetes. State and local health departments, correctional facilities, public health clinics, and school districts procure meglitinides as part of pharmaceutical inventory for patient care, inmate medical services, and student health programs. The code applies to both brand-name formulations (such as Prandin) and generic equivalents, typically acquired through competitive pharmaceutical bidding processes, group purchasing organizations, or state health agency contracts.

The source provided contains no recent state or local contract opportunities posted under UNSPSC 51183111. Without posted RFP, RFQ, IFB, or ITB records, no geographic concentration, issuing-body patterns, or representative solicitation examples can be identified from current procurement activity.